Home > Resources > Whitepapers > The Evolution Of Biopharmaceutical Facility Designs

The Evolution Of Biopharmaceutical Facility Designs

August 22, 2018

In the lifecycle of pharmaceutical and biopharmaceutical commercial manufacturing, the one constant has been changed. With the advent of modern therapeutics, large-scale commercial manufacturing became commonplace. And typically such manufacturing produced large-scale purpose-built facilities designed to satisfy “blockbuster” global demand.

Spotlight

Forge Biologics

Forge is a gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality.

OTHER WHITEPAPERS

70 years of wood modifcation with fungi

whitePaper | March 18, 2022

Fungi are usually seen by the wood used only as destroyers or parasites. Material infestation should be avoided as far as possible for wood preservation reasons.

Gene, Cell, & RNA Therapy Landscape

whitePaper | January 24, 2022

The American Society of Gene & Cell Therapy (ASGCT) is the primary professional membership organization.

6 Strategies to Stimulate Patient Engagementin Rehab Therapy

whitePaper | August 25, 2022

Patient engagement has become a measure of healthcare analytics that many in rehab therapy have sought to quantify.

A REVIEW OF THE RESEARCH TRENDS AND DEVELOPMENTS

whitePaper | May 9, 2022

In the last decade, there has been an encouraging shift in research, clinical development, and commercial activity to exploit the many biological roles of ribonucleic acid (RNA) for use in medicine.

Benefit-Risk Considerations for Product Quality Assessments; Guidance for Industry; DRAFT GUIDANCE

whitePaper | May 10, 2022

This guidance describes the benefit-risk principles applied by FDA when conducting product quality-related assessments of chemistry, manufacturing, and controls (CMC)2 19 information 20 submitted for FDA assessment as part of original new drug applications (NDAs) under section

More Whitepapers